Bionano Genomics announces proposed public offer to purchase common shares


SAN DIEGO, January 7, 2021 (GLOBE NEWSWIRE) – BIONANO GENOMICS, INC. (Nasdaq: BNGO), today announced its intention to offer and sell, subject to market and other conditions, public offering common shares. There can be no guarantee as to whether or when the offer can be made, nor as to the actual size or conditions of the offer. Bionano also plans to grant subscribers a 30-day option to purchase up to an additional 15% of the number of common shares offered under the offer, to cover over-allotments, if any. All of the shares in the proposed offering must be sold by Bionano.

Oppenheimer & Co. Inc. is acting as the sole accounting manager for the offering. BTIG, LLC acts as principal manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC act as co-managers.

The shares are being offered in accordance with a “provisional” registration statement on Form S-3 (File No. 333-245762) previously filed on August 14, 2020 and declared effective by the Securities and Exchange Commission (SEC) on August 25, 2020 A preliminary prospectus supplement and related prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at Where available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Oppenheimer & Co. Inc., Attn .: Syndicate Prospectus Department, 85 Broad Street , 26e Floor, New York, New York 10004, by phone at 212-667-8055, or by email at [email protected]

Before investing in the Offer, you should read the entire preliminary prospectus supplement and the accompanying prospectus and other documents that Bionano has filed with the SEC which are incorporated by reference in the preliminary prospectus supplement. and the accompanying leaflet, which provide more information. on Bionano and the offer.

This press release does not constitute an offer to sell or a solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or other jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of such state or other jurisdiction.

About Bionano Genomics

Bionano is a genome analysis company that provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and provides diagnostic testing for people with spectrum disorders. autistic (ASD) and other neurodevelopmental disabilities through its Lineagen activity. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system. researchers who prefer not to adopt the Saphyr system in their laboratories.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements about Bionano’s expectations regarding the completion, timing and size of the project. public offer. Words such as “may”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “intend” and similar expressions (as well as other words or expressions which may reference to future events, conditions or circumstances) convey uncertainty about future events or results and are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. The risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions associated with the Offer, as well as the risks and uncertainties associated with Bionano’s business, are among the factors that could cause the actual results of Bionano to differ materially. those indicated in forward-looking statements. and the general financial position, including the risks and uncertainties described in Bionano’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the SEC, and subsequent filings by Bionano with of the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Bionano assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. , unless this may be required by law.


Company contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]

Source link